Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Официальное название

An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors

Обзор

This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.

Вмешательства

• Препарат AK119
  AK119 is an anti-CD73 monoclonal antibody.
• Препарат AK112
  AK112 is a bispecific monoclonal antibody against VEGF and PD-1.

Первичные конечные точки

• Number of subjects with dose limiting toxicities (DLTs) [Срок оценки: During the first three weeks]
• Number of subjects with adverse events (AEs) [Срок оценки: From the time of informed consent signed through 90 days after the last dose of study drug.]
• Objective Response Rate (ORR) [Срок оценки: Up to 2 years]

Вторичные конечные точки (6)

• Progression free survival (PFS) [Срок оценки: Up to 2 years]
• Disease control rate (DCR) [Срок оценки: Up to 2 years]
• Duration of response (DoR) [Срок оценки: Up to 2 years]
• Time to response (TTR) [Срок оценки: Up to 2 years]
• Time to progression (TTP) [Срок оценки: Up to 2 years]
• Overall survival (OS) [Срок оценки: Up to 2 years]

Критерии участия

Критерии включения

• Voluntarily written informed consent and agree to comply with all protocol-specified procedures and follow-up evaluations
• Age ≥ 18 years and ≤ 75 years
• Histologically or cytologically-confirmed diagnosis of advanced/unresectable solid tumor that have been progressed or intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists
• Measurable lesion based on RECIST v1.1
• ECOG status of 0 or 1
• Life expectancy ≥ 3 months
• Adequate organ function
• Women of childbearing potential and men with female partners of childbearing potential must agree to use effective contraception during treatment and for at least 120 days following the last dose of study treatment

Критерии исключения

• Known other active malignancy within 3 years prior to the first dose of investigational product, with the exception of early stage cancers that have treated with curative intent
• Currently participating in another study unless it is an observational, non-interventional clinical study or a follow-up period of an interventional study
• Received systemic antineoplastic therapy ( e.g. chemotherapy, radiotherapy, immunotherapy) within 4 weeks prior to the first dose of investigational product; received small-molecule anticancer agents within 2 weeks prior to the first dose of investigational product
• In addition to anti-PD-(L)1 monoclonal antibody, prior exposure to other immune checkpoint inhibitors or any other treatment directed to tumor immune mechanism
• Prior therapy targeting CD73 or CD39 or the adenosine signalling pathway
• Treatment with non-steroidal anti-inflammatory drugs, anti-platelet agents or anticoagulants within 7 days prior to the first dose of investigational product
• Current dependency on systemic therapy with glucocorticoids (>10 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose of investigational product
• Presence of spinal cord compression or active brain metastases
• Uncontrolled pleural effusion, pericardial effusion or ascites requiring repeated drainage
• History or presence of a serious hemorrhage or known bleeding tendency within 3 months
• Active autoimmune disease that has required systemic treatment in past 2 years
• Clinically significant cardiovascular disease
• History of interstitial lung disease or noninfectious pneumonitis
• Received systemic anti-infective therapy (excluding antiviral therapy for hepatitis B or C) within 14 days prior to the first dose of investigational product
• Major surgical procedure or serious trauma within 28 days prior to the first dose of investigational product
• History of immunodeficiency, human immunodeficiency virus infection (HIV)
• Active tuberculosis or syphilis infection
• History of organ transplantation or allogeneic haematopoietic stem cell transplantation
• Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 (NCI-CTCAE version 5.0)
• Any other conditions that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Последовательный дизайн

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Peking Union Medical College Hospital — Пекин

Идентификаторы

NCT: NCT05689853 · Ak119-105

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗